Treating Reactive Arthritis When Conventional Therapy Has Not Achieved an Adequate Response

Clinical Scenario

This protocol applies to patients with reactive arthritis who remain refractory to conventional treatment. A targeted escalation approach is defined, with specific, measurable outcomes used to assess whether the response is adequate at 6 months.

Treatment Goals at 6 Months

At least 30% decrease in tender joint count
At least 30% decrease in swollen joint count
At least 2-point decrease on a 10-point pain VAS
CRP level below 20 mg/litre

Treatment Approach — Partial Overview

In patients who have not responded adequately to conventional therapy, this protocol involves a biological agent targeting a specific pro-inflammatory pathway. Agent selection and administration details depend on the individual clinical picture.

The complete regimen — including agent choice, schedule, and monitoring criteria — is in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

The largest patient series available has been reported by Flagg et al., who conducted an open-label trial involving 16 patients with undifferentiated or reactive arthritis treated for 6 months with etanercept 25 mg subcutaneous twice a week.

For this reason, caution on TNF inhibitor treatment of ReA patients is advisable, limiting this option to patients refractory to conventional therapy, at least until further studies will definitely exclude safety issues.

2 of the following 3 assessment measures: at least a 2-point decrease in the 10-point VAS for pain, at least a 30% decrease in tender joint count, and at least a 30% decrease in swollen joint count.

Complete remission: complete resolution of the clinical manifestation, normalisation of inflammatory markers, no recurrence of the arthritis.

View source ↗